Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.28% $70.57
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 1 249.46 mill |
EPS: | 3.03 |
P/E: | 23.29 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 17.71 mill |
Avg Daily Volume: | 0.173 mill |
RATING 2024-04-26 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Buy | |
Return On Asset: | Strong Buy | |
DE: | Sell | |
P/E: | Buy | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 23.29 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
3.96x |
Company: PE 23.29 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$26.36 (-62.64%) $-44.21 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 67.82 - 73.33 ( +/- 3.90%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Kozarich John W | Buy | 2 893 | Common Stock |
2024-04-24 | Kozarich John W | Sell | 2 893 | Non-Qualified Stock Option (right to buy) |
2024-03-25 | Davis Todd C | Buy | 3 556 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 156 | Common Stock |
2024-03-25 | Davis Todd C | Buy | 2 855 | Common Stock |
INSIDER POWER |
---|
76.80 |
Last 99 transactions |
Buy: 847 979 | Sell: 102 779 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $70.57 (0.28% ) |
Volume | 0.0856 mill |
Avg. Vol. | 0.173 mill |
% of Avg. Vol | 49.44 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $75.38 | N/A | Active |
---|
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.